Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 May;8(1):e000954.
doi: 10.1136/bmjdrc-2019-000954.

Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial

Louis Potier  1   2 , Maud François  3 , Dured Dardari  4 , Marilyne Feron  5 , Narimene Belhatem  5 , Estelle Nobecourt-Dupuy  6 , Manuel Dolz  7 , Lyse Bordier  7 , Roxane Ducloux  8 , Abdelkader Chibani  9 , Dominique-François Eveno  10 , Teresa Crea Avila  11 , Ariane Sultan  12   13 , Laurence Baillet-Blanco  14 , Vincent Rigalleau  14   15 , Elise Gand  16 , Pierre-Jean Saulnier  16 , Gilberto Velho  17 , Ronan Roussel  5   17 , Quentin Pellenc  18 , Jean-Claude Dupré  5 , Dominique Malgrange  3 , Michel Marre  5 , Kamel Mohammedi  14   15 ; ORTHODIAB study group
Affiliations
Randomized Controlled Trial

Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial

Louis Potier et al. BMJ Open Diabetes Res Care. 2020 May.

Abstract

Introduction: The offloading is crucial to heal neuropathic diabetic foot ulcer (DFU). Removable offloading are the most used devices. Orthèse diabète is a new customized removable knee-high offloading device immobilizing foot and ankle joints, with some specific and innovative features that may improve offloading. We aimed to evaluate the efficiency of this device in DFU healing.

Research, design and methods: The evaluation of Offloading using a new removable ORTHOsis in DIABetic foot study is a French multicenter (13 centers) randomized controlled trial with blinded end points evaluation. Adults with neuropathic DFU were randomly assigned to either Orthèse Diabète (experimental device), or any type of conventional (usually used in France) removable offloading devices (control group). The primary outcome was the 3-month proportion of patients with fully healed DFU.

Results: Among 112 randomized patients (men 78%, age 62±10 years), the primary outcome occurred in 19 (33%) participants using conventional device vs 19 (35%) Orthèse Diabète users (p=0.79). Study groups were also comparable in terms of prespecified secondary end points including occurrence of new DFU (25% vs 27% in conventional and experimental groups), ipsilateral lower-limb amputation (4% vs 10%) or infectious complications (14% vs 13%) (p>0.05 for all). Adverse events were comparable between groups, including 4 deaths unrelated to study allocation (1 sudden death, 2 ventricular arrhythmias and 1 pancreatic cancer). Adverse events believed to be related to the device were higher in the Orthèse Diabète group than in the control group (15% vs 4%). Orthèse Diabète was less frequently worn than conventional devices (46% vs 66%, p=0.04).

Conclusions: Orthèse Diabète, a new removable offloading orthosis immobilizing foot and ankle joints did not show superiority compared with conventional removable devices in neuropathic DFU healing and cannot be recommended to heal DFU.

Trial registration number: NCT01956162.

Keywords: foot ulcer; off-loading devices; randomized clinical trials; wound healing.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LP reports receiving personal fees from Novo Nordisk, Lilly, Sanofi and Servier and grants from Sanofi, outside the submitted work; RR is an advisory panel member for AstraZeneca, Sanofi, MSD, Eli Lilly, Novo Nordisk, Vaiomer and Physiogenex; is a speaker for Bayer and Servier and has received research funding and provided research support to Danone Research, Diabnext, Boehringer-Ingelheim, Amgen, Sanofi and Novo Nordisk. MM reports receiving personal fees from Novo Nordisk, Sanofi, Eli Lilly, Servier, Merck, Sharp and Dohme, Abbott, Novartis and AstraZeneca and grant support from Novo Nordisk, Sanofi, Eli Lilly, Merck Sharp and Dohme and Novartis, outside the submitted work; KM reports receiving personal fees from Novo Nordisk, Sanofi, Eli Lilly, Proteor and AstraZeneca, and travel support from Novo Nordisk, Sanofi, Boehringer Ingelheim and Takeda outside the submitted work.

Figures

Figure 1
Figure 1
Schematic illustration of ‘Orthèse Diabète’ and its different components.
Figure 2
Figure 2
Trial profile. ITT, intention-to-treat; PP, per-protocol.
See this image and copyright information in PMC

References

    1. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–75. 10.1056/NEJMra1615439 - DOI - PubMed
    1. Resnick HE, Carter EA, Sosenko JM, et al. . Incidence of lower-extremity amputation in American Indians: the strong heart study. Diabetes Care 2004;27:1885–91. 10.2337/diacare.27.8.1885 - DOI - PubMed
    1. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, et al. . The global burden of diabetic foot disease. Lancet 2005;366:1719–24. 10.1016/S0140-6736(05)67698-2 - DOI - PubMed
    1. Moxey PW, Hofman D, Hinchliffe RJ, et al. . Epidemiological study of lower limb amputation in England between 2003 and 2008. Br J Surg 2010;97:1348–53. 10.1002/bjs.7092 - DOI - PubMed
    1. Fromy B, Abraham P, Bouvet C, et al. . Early decrease of skin blood flow in response to locally applied pressure in diabetic subjects. Diabetes 2002;51:1214–7. 10.2337/diabetes.51.4.1214 - DOI - PubMed

Publication types

Associated data